5‐Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms

Jonathan J. Lee; Ricardo E. Vilain; Scott R. Granter; Nina R. Hu; Scott C. Bresler; Shuyun Xu; Alexander Frank; Martín C. Mihm; Robyn P.M. Saw; Christopher D.�M. Fletcher; Richard A Scolyer; Gëorge F. Murphy; Christine G. Lian

doi:10.1111/cup.12880

Back

5‐Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms

Article 2016 en

Abstract

1 min read

Loss of 5-hmC may be helpful in differentiating benign, diagnostically challenging, heavily pigmented melanocytic tumors from those with malignant potential. The intermediate to low 5-hmC immunoreactivity in atypical DPNs, PEMs and so-called MELTUMP categories further underscores the need to consider these neoplasms as having some potential for lethal biological behavior.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2011

Approaches to classification and management of histologically ambiguous/ borderline / primary cutaneous melanocytic tumours

Richard A Scolyer, Stanley W. McCarthy, John F. Thompson

Article2007

Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors)

Rajmohan Murali, Raghwa Sharma, John F. Thompson, Jonathan R. Stretch, C. Soon Lee, Stanley W. McCarthy, Richard A Scolyer

Article2014

Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors

Allison R. Larson, Karen Dresser, Qian Zhan, Cecilia Lezcano, Bruce A. Woda, Benafsha Yosufi, John F. Thompson, Richard A Scolyer, Martín C. Mihm, Yujiang Geno Shi, Gëorge F. Murphy, Christine G. Lian

Letter2010

Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential

Cathy Lim, Rajmohan Murali, Stanley W. McCarthy, Joseph Krivanek, Richard A Scolyer

Article2010

Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy.

Richard A Scolyer, Rajmohan Murali, Stanley W. McCarthy, John F. Thompson